



**Cure VCP Disease, Inc.**

**Financial Statements**  
**For the Years Ended December 31, 2024 and 2023**

**Cure VCP Disease, Inc.**  
**Statements of Financial Position**  
**December 31, 2024 and 2023**

<u>Assets</u>	<u>December 31, 2024</u>	<u>December 31, 2023</u>
Current Assets		
Cash and Cash Equivalents	\$ 411,385	\$ 475,504
Accounts Receivable	20,925	9,463
Prepaid Expenses	50	4,000
Total Current Assets	<u>432,360</u>	<u>488,967</u>
<b>Total Assets</b>	<u><u>\$ 432,360</u></u>	<u><u>\$ 488,967</u></u>
 <u>Liabilities and Net Assets</u>		
Current Liabilities		
Accounts Payable	<u>5,615</u>	<u>799</u>
Total Current Liabilities	<u>5,615</u>	<u>799</u>
Net Assets		
Net Assets without Donor Restrictions	421,991	276,064
Net Assets with Donor Restrictions	<u>4,754</u>	<u>212,104</u>
Total Net Assets	<u>426,745</u>	<u>488,168</u>
<b>Total Liabilities and Net Assets</b>	<u><u>\$ 432,360</u></u>	<u><u>\$ 488,967</u></u>

**Cure VCP Disease, Inc.**  
**Statements of Activities**  
**For the Years Ended December 31, 2024 and 2023**

	<u>2024</u>			<u>2023</u>		
	without Donor Restrictions	Net Assets with Donor Restrictions	Total	without Donor Restrictions	Net Assets with Donor Restrictions	Total
<b>Revenues and Other Support</b>						
Contribution Income	\$ 140,303	\$ 25,000	\$ 165,303	\$ 98,181	\$ 200,000	\$ 298,181
Fundraising Income, net	124,638	-	124,638	118,708	-	118,708
Program Income - Scientific Conference	18,438	-	18,438	14,596	-	14,596
Release from Restrictions	232,350	(232,350)	-	206,514	(206,514)	-
Total Revenues and Other Support	<u>515,729</u>	<u>(207,350)</u>	<u>308,379</u>	<u>437,999</u>	<u>(6,514)</u>	<u>431,485</u>
<b>Expenses</b>						
Program Expenses	276,428	-	276,428	276,764	-	276,764
General and Administrative Expenses	38,171	-	38,171	19,977	-	19,977
Fundraising Expenses	55,203	-	55,203	53,387	-	53,387
Total Expenses	<u>369,802</u>	<u>-</u>	<u>369,802</u>	<u>350,128</u>	<u>-</u>	<u>350,128</u>
<b>Change in Net Assets</b>	145,927	(207,350)	(61,423)	87,871	(6,514)	81,357
<b>Net Assets, Beginning of Year</b>	276,064	212,104	488,168	188,193	218,618	406,811
<b>Net Assets, End of Year</b>	<u>\$ 421,991</u>	<u>\$ 4,754</u>	<u>\$ 426,745</u>	<u>\$ 276,064</u>	<u>\$ 212,104</u>	<u>\$ 488,168</u>

The accompanying notes are an integral part of these financial statements

**Cure VCP Disease, Inc.**  
**Statement of Functional Expenses**  
**For the Year Ended December 31, 2024**

	Program	Management and General	Fundraising	Total
Professional Fees	\$ 51,823	\$ 27,899	\$ 47,500	\$ 127,222
Grants	81,660	-	-	81,660
Compensation	71,265	197	5,442	76,904
Conferences	54,793	-	-	54,793
Travel	8,985	-	-	8,985
Technology	3,138	443	1,754	5,335
Miscellaneous	4,342	2,297	-	6,639
Insurance	10	3,119	3	3,132
Office Expenses	412	3,121	504	4,037
Bank Service Charges	-	1,095	-	1,095
<b>Total Functional Expenses</b>	<b>\$ 276,428</b>	<b>\$ 38,171</b>	<b>\$ 55,203</b>	<b>\$ 369,802</b>

The accompanying notes are an integral part of these financial statements.

**Cure VCP Disease, Inc.**  
**Statement of Functional Expenses**  
**For the Year Ended December 31, 2023**

	Program	Management and General	Fundraising	Total
Professional Fees	\$ 86,939	\$ 9,094	\$ 14,750	\$ 110,783
Grants	62,123	-	-	62,123
Compensation	71,226	1,210	36,331	108,767
Conferences	29,870	150	-	30,020
Travel	20,726	-	1,224	21,950
Technology	1,650	2,066	1,029	4,745
Miscellaneous	3,853	498	-	4,351
Insurance	-	2,760	-	2,760
Office Expenses	377	2,760	-	3,137
Bank Service Charge	-	1,439	53	1,492
<b>Tota Educational Resources</b>	<b>\$ 276,764</b>	<b>\$ 19,977</b>	<b>\$ 53,387</b>	<b>\$ 350,128</b>

The accompanying notes are an integral part of these financial statements.